Three Research Peptides, One Metabolic Question

The short version

Peptide Supplied is a reading desk, not a store. It collects what the published research literature actually says about three peptides that keep coming up in conversations about metabolic regulation and weight management: retatrutide, tesamorelin, and MOTS-c. A peptide is a short chain of amino acids — the same building blocks as proteins, only far smaller. Each of these three has been studied because it appears to influence some part of the body's metabolic machinery: suppressing appetite and mobilizing stored energy, stimulating the growth hormone axis to reduce visceral fat, or activating the AMPK energy-sensing pathway in muscle.

This desk does one job: it tells you, in plain language with citations, what each peptide was tested on, in which species (clinical trials, animal models, or both), and how far that evidence actually reaches. The evidence base differs sharply across the three. None of them carries any dosing or medical advice here.

What are research peptides?

Proteins in your body — an enzyme in your gut, a signaling hormone, collagen in a tendon — are long chains of amino acids folded into a specific shape. A peptide is a much shorter chain of the same amino acids, sometimes only a handful of links long. Because they are small and specific, peptides can act like keys that fit particular receptors on the surface of cells, switching certain pathways on or off.

A research peptide is one that has been synthesized and studied in the laboratory — in cell cultures, in animals, or in clinical trials — but either has not been approved by a regulator for general use, or has approval that is narrowly scoped (a specific indication, a specific population). Sellers describe unapproved compounds as being for laboratory research only, and that framing matters: it means dosing, long-term safety, and real-world effectiveness in general human populations are often not fully established. When this desk reports a number from a study, it reports it exactly as the study did — for example, mean body-weight change -24.2% at 12 mg in 338 obese adults over 48 weeks — never as a recommendation.

How these three fit into metabolic research

The three peptides on this desk approach metabolic regulation from different levels of the system, which is why they sit together.

• Retatrutide is the lead. It is a 39-amino-acid investigational compound that hits three receptors simultaneously — GIP, GLP-1, and glucagon — producing appetite suppression, improved glucose-dependent insulin secretion, and increased energy expenditure. Phase 2 trials in humans showed a mean ~24% body-weight reduction at 48 weeks ^[4], the largest published single-agent metabolic signal for any peptide class. It remains investigational and is not approved by any regulator.
• Tesamorelin operates upstream: it binds the growth hormone-releasing hormone receptor on pituitary cells, stimulating the body's own pulsatile GH secretion and driving visceral fat reduction. Unlike the others, it carries FDA approval — but only for a specific population (HIV-associated lipodystrophy) ^[9]. Its generalizability to other contexts is mechanistically plausible but unestablished by large trials.
• MOTS-c is the deepest outlier. It is a 16-amino-acid peptide encoded not in nuclear DNA but in the mitochondrial genome, discovered less than a decade ago. In animal models it activates AMPK, improves glucose handling, and enhances physical performance across age groups ^[16]. There are no published human intervention trials; all efficacy data are preclinical.

Together they illustrate the metabolic research landscape from three angles: receptor-level appetite and energy signaling, GH-axis fat mobilization, and cellular energy sensing. Read each one in full, or compare these peptides side by side.

A note on how this desk reads the literature

Peptide Supplied is a cross-referenced literature digest. Each peptide page summarizes the peer-reviewed studies for that compound, cites them by number, and links to a single shared references list that aggregates every source across all three. Where the evidence is thin, preclinical, or narrowly scoped, we say so plainly — that candor is part of the record. We describe research findings and the cited cautions that come with them; we do not recommend, prescribe, or sell. The goal is a blunt, accurate map of what is known, so a reader can see where the science is solid and where it is still mostly promise.